About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Imatinib in Systemic Sclerosis | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1/2NCT00506831

Imatinib in Systemic Sclerosis

Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin and internal organs and widespread vasculopathy. Patients with SSc are classified according to the extent of cut...

Lead sponsor: Stanford University•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Stanford University

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adults with refractory diffuse or limited SSc and any or all of the following: Progressive cutaneous fibrosis, Interstitial lung disease, Pulmonary arterial hypertension, Digital ulcerations.

Exclusion Criteria

•Uncontrolled congestive heart failure, hypertension, or coronary artery disease.
•HIV, hepatitis B, and/or hepatitis C infection. Serious infection within the past month. Significant hematologic, renal, or hepatic abnormalities. Concurrent use of intravenous immunoglobulin or cyclophosphamide within 4 weeks of the first treatment dose.
•Concurrent use of a biologic agent (ie. etanercept, infliximab, adalimumab, abatacept) within 8 weeks of the first treatment dose (6 months for rituximab).
•Women who are pregnant or breastfeeding.

Related studies

RECRUITINGPhase 2/3

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

NCT05878717 · Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic

Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis

NCT06256575 · Scleroderma, Systemic, Digital Ulcer

Pilot Study of Description of Cicatrisation Rates of Digital Ulcers in Systemic Scleroderma

NCT04319120 · Scleroderma, Systemic

Active Not RecruitingNA

Development and Evaluation of an Evidence-based Education Program for People With Hand Dysfunction in Scleroderma

NCT06697561 · Scleroderma, Systemic

Profibrosing Role of B Lymphocytes in Patients With Systemic Sclerosis.

NCT03559465 · Scleroderma, Systemic

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 13, 2018Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1/PHASE2

Enrollment9

Start dateJul 2007

Last updatedAug 13, 2018

Condition

Scleroderma, Systemic

Locations shown

Stanford University School of Medicine

Stanford, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 13, 2018Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions